ABIVAX SIGNS AGREEMENT WITH THE FINLAY INSTITUTE

November 12, 2014
PDF Version
Details
Published on Wednesday, 12 November 2014 13:58

ABIVAX signs agreement with the Finlay Institute to commercialise meningococcal and typhoid vaccines in Asia and Latin America. Under the terms of the agreement, ABIVAX will gain exclusive and non-exclusive distribution rights for three vaccines currently marketed successfully by The Finlay Institute in Cuba :

  • Typhoid: vax‐TyVi – targeting Typhoid
  • Meningococcal: VA‐MENGOC‐BC – targeting Groups B & C Meningococcus
  • Leptospirosis: vax‐SPIRAL – targeting Leptospirosis